Novartis AG vs Novo Nordisk A/S: Strategic Comparison
Key Differences at a Glance
| Field | Novartis AG | Novo Nordisk A/S |
|---|---|---|
| Revenue | $54.5B | $46.0B |
| Founded | 1996 | 1989 |
| Employees | 75,267 | 69,505 |
| Market Cap | $274.1B | $550.0B |
| Headquarters | Switzerland | Denmark |
Quick Stats Comparison
| Metric | Novartis AG | Novo Nordisk A/S |
|---|---|---|
| Revenue | $54.5B | $46.0B |
| Founded | 1996 | 1989 |
| Headquarters | Basel, Switzerland | Bagsvaerd, Denmark |
| Market Cap | $274.1B | $550.0B |
| Employees | 75,267 | 69,505 |
Novartis AG Revenue vs Novo Nordisk A/S Revenue — Year by Year
| Year | Novartis AG | Novo Nordisk A/S | Leader |
|---|---|---|---|
| 2025 | $54.5B | $46.0B | Novartis AG |
| 2024 | $50.3B | $42.7B | Novartis AG |
| 2023 | $45.4B | $34.0B | Novartis AG |
Business Model Breakdown
Overview: Novartis AG vs Novo Nordisk A/S
This in-depth comparison examines Novartis AG and Novo Nordisk A/S across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Novartis AG on its own, evaluating Novo Nordisk A/S, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Novartis AG and Novo Nordisk A/S is widest.
On the headline numbers, Novartis AG reports annual revenue of $54.5B against $46.0B for Novo Nordisk A/S, while their respective market capitalizations stand at $274.1B and $550.0B. Novartis AG is headquartered in Switzerland and Novo Nordisk A/S operates from Denmark, and those different home markets shape how each company competes.
Novartis AG: Novartis AG is a public company listed on NYSE under ticker NVS. Novartis makes money by discovering, developing, manufacturing, and commercializing patented medicines across cardiovascular, renal and metabolic, immunology, neuroscience, and oncology markets.
Novo Nordisk A/S: Novo Nordisk A/S is a public company listed on NYSE under ticker NVO. Novo Nordisk makes money by developing and selling prescription medicines for diabetes, obesity, rare blood disorders, rare endocrine disorders, and related chronic diseases.
Business Models: How Novartis AG and Novo Nordisk A/S Make Money
Novartis AG and Novo Nordisk A/S pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Novartis AG and Novo Nordisk A/S.
Novartis AG business model: Novartis makes money by discovering, developing, manufacturing, and commercializing patented medicines across cardiovascular, renal and metabolic, immunology, neuroscience, and oncology markets.
Novo Nordisk A/S business model: Novo Nordisk makes money by developing and selling prescription medicines for diabetes, obesity, rare blood disorders, rare endocrine disorders, and related chronic diseases.
Competitive Advantage: Novartis AG vs Novo Nordisk A/S
The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Novartis AG stack up against those of Novo Nordisk A/S.
Novartis AG competitive advantage: Novartis's advantage is a focused patented-medicine portfolio, global commercial reach, scale in clinical development, and specialty platforms such as radioligand therapy.
Novo Nordisk A/S competitive advantage: Novo Nordisk's advantage is deep GLP-1 science, diabetes and obesity scale, global manufacturing, payer experience, and one of the world's strongest chronic-care franchises.
Growth Strategy: Where Novartis AG and Novo Nordisk A/S Are Headed
Future prospects matter as much as current results. The growth strategies below explain how Novartis AG and Novo Nordisk A/S each plan to expand from here.
Novartis AG growth strategy: Novartis AG's growth strategy centers on this advantage: Novartis's advantage is a focused patented-medicine portfolio, global commercial reach, scale in clinical development, and specialty platforms such as radioligand therapy.
Novo Nordisk A/S growth strategy: Novo Nordisk A/S's growth strategy centers on this advantage: Novo Nordisk's advantage is deep GLP-1 science, diabetes and obesity scale, global manufacturing, payer experience, and one of the world's strongest chronic-care franchises.
Financial Picture: Novartis AG vs Novo Nordisk A/S
A closer look at the financial trajectory of Novartis AG and Novo Nordisk A/S rounds out the comparison.
Novartis AG: Novartis AG reported FY2025 revenue of $54.532B and net income of $13.967B.
Novo Nordisk A/S: Novo Nordisk A/S reported FY2025 revenue of DKK 309.064B (about $46.0B) and net income of DKK 102.434B (about $15.2B).
Company-Specific SWOT Notes
Novartis AG
After Sandoz and Alcon separations, Novartis is concentrated around branded, higher-margin medicines and specialty platforms.
Large franchises can lose sales quickly when exclusivity ends or payers switch patients to generics and biosimilars.
Radioligand therapy, oncology, immunology, and cardiovascular launches can offset mature-product pressure.
Drug-price controls, reimbursement restrictions, safety findings, and clinical failures can materially affect growth.
Novo Nordisk A/S
Novo Nordisk has global scale, clinical depth, and manufacturing experience in diabetes and obesity GLP-1 medicines.
A large share of investor expectations depends on continued Ozempic and Wegovy growth.
Obesity care, cardiovascular outcomes, oral formulations, and broader metabolic indications can expand the addressable market.
Rival incretin drugs, compounding, payer restrictions, safety scrutiny, and supply constraints can pressure growth.
Head-to-Head Scorecard
| Category | Winner | Why |
|---|---|---|
| Revenue Scale | Novartis AG | Novartis AG reports the larger revenue base ($54.5B), which serves as a core operational scale signal. |
| Profitability Potential | Comparable | Both organizations prioritize market penetration or are at equivalent reporting tiers. |
| Company Age | Novo Nordisk A/S | Founded in 1996 vs 1989. The earlier pioneer typically commands longer historical institutional legacy. |
| Innovation Moat | Novartis AG | Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity. |
| Scale (Employees) | Novartis AG | A significantly larger reported workforce supports enhanced global distribution capability. |
| Market Cap | Novo Nordisk A/S | Higher public valuation denotes greater forward-looking investor conviction in earnings potential. |
| Future Outlook | Tied | Strategic auditing assesses that both maintain defensive leadership vectors within their core market clusters. |
Who Wins Each Category?
Novartis AG reports the larger revenue base ($54.5B), which serves as a core operational scale signal.
Both organizations prioritize market penetration or are at equivalent reporting tiers.
Founded in 1996 vs 1989. The earlier pioneer typically commands longer historical institutional legacy.
Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity.
A significantly larger reported workforce supports enhanced global distribution capability.
Who Wins: Novartis AG or Novo Nordisk A/S?
Reviewed by Swet Parvadiya, May 2026 - Author Profile
Our analysts compile business strategy profiles from public financial filings, press releases, and analyst reports. Each profile is reviewed for accuracy before publication by our editorial desk and updated on a rolling basis.
Frequently Asked Questions: Novartis AG vs Novo Nordisk A/S
Is Novartis AG better than Novo Nordisk A/S?
Verdict: Between Novartis AG and Novo Nordisk A/S, Novartis AG is the stronger overall option based on higher annual revenue. The decision still depends on which factors matter most for your needs, but on the weight of the evidence above, Novartis AG comes out ahead in this Novartis AG vs Novo Nordisk A/S comparison.
Who earns more — Novartis AG or Novo Nordisk A/S?
Novartis AG earns more with $54.5B in annual revenue versus Novo Nordisk A/S's $46.0B. Novartis AG leads on total revenue based on latest verified figures.
Which company has higher revenue — Novartis AG or Novo Nordisk A/S?
Novartis AG reported $54.5B, while Novo Nordisk A/S reported $46.0B. The revenue leader is Novartis AG based on latest verified figures.
Novartis AG revenue vs Novo Nordisk A/S revenue — which is higher?
Novartis AG revenue: $54.5B. Novo Nordisk A/S revenue: $46.0B. Novartis AG has the larger revenue base of the two companies.
Sources & References
- Novartis AG Corporate Website
- Novartis AG Annual Report 2025 - Revenue and Financial Data
- sec.gov
- novartis.com
- Novo Nordisk A/S Corporate Website
- Novo Nordisk A/S Annual Report 2025 - Revenue and Financial Data
- sec.gov
- novonordisk.com